Obstetrics and Gynaecology Department of Hospital Universitari del Mar, Passeig Marítim, 25-29, 08003, Barcelona, Catalonia, Spain.
Universitat Autónoma de Barcelona, Plaza Cívica, Campus de la UAB, 08193, Bellaterra, Catalonia, Spain.
Sci Rep. 2017 Aug 9;7(1):7687. doi: 10.1038/s41598-017-08048-0.
To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154-168) as compared with 146 months (95% CI, 123-160) for those with CD133- tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149-168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251-17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.
为了评估 CD133 表达对子宫内膜样型子宫内膜癌（EEC）预后的影响。我们回顾性评估了 116 例手术治疗的国际妇产科联盟（FIGO）I-III 期 EEC 组织微阵列中 CD133 的表达。将 CD133 表达细胞≥10%的肿瘤视为 CD133 阳性（CD133+）。根据 CD133 表达、临床和病理参数、无进展生存期（PFS）和总生存期（OS）进行评估。在研究的 EEC 中，85.2%显示 CD133 表达细胞。只有 61%（n=66）的 EEC 呈现≥10%的 CD133 表达细胞，并被认为是 CD133+。CD133+肿瘤患者的平均 OS 为 161 个月（95%CI，154-168），而 CD133-肿瘤患者的平均 OS 为 146 个月（95%CI，123-160）（p=0.012）。CD133+肿瘤患者的平均 PFS 为 159 个月（95%CI，149-168），而 CD133-肿瘤患者的平均 PFS 为 147 个月（95%CI，132-161）（p=0.014）。CD133+肿瘤更不可能发生血管侵犯（p=0.010），更可能分化良好（p=0.034）。CD133+肿瘤预测 EEC 患者的 OS 和 PFS 有利，风险比为 4.731（95%CI，1.251-17.89；p=0.022）。CD133+肿瘤状态与 EEC 的良好预后相关。我们的研究结果与针对脑和结直肠癌的研究一致。
